Clinical Trial: A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612150) titled 'A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease' on May 21.

Brief Summary: The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as compared to participants receiving placebo.

Study Start Date: Aug. 01, 2026

Study Type: INTERVENTIONAL

Condition: Alzheimer Disease

Intervention: DRUG: TML-6

TML-6 tablets for oral administration.

OTHER: Placebo

TML-6 matching placebo tablets for oral administration...